PLEVRAL BO'SHIKDA EKSUDAT TO'PLASHISH INTENSUSLIGINI KO'P FAKTORIAL TAHLILI
##article.subject##:
PAD sabablari, EKG (kerak bo'lsa, EchoCG, FVD), pulsoksimetriya, Ultratovush tekshiruvi, Kompyuter tomografiyasi (KT)##article.abstract##
Malign gidrotoraksni davolash birinchi navbatda plevra bo'shlig'ida suyuqlik to'planishini yo'q qilishdan iborat bo'lib, bu ikkinchisining to'planish intensivligiga bog'liq. To'liq rivojlanmagan muammo - bu kasallikning natijasiga ta'sir qiluvchi prognostik omillar. Bugungi kunga qadar ushbu patologiyani davolashning etarli usullari aniqlanmagan. Davolashning dorivor, radiatsiyaviy va jarrohlik usullariga ko'rsatmalar standartlari ishlab chiqilmagan.Kasallikning intensiv rivojlanishi o'simta jarayonining agressivligini, uning kengayishini ko'rsatadi. Aksincha, sekin rivojlanish, kamroq intensiv rivojlanish kasallikning nisbatan qulay kursini ko'rsatadi. Tadqiqotimizga kiritilgan bemorlarda 6 oydan 5 yilgacha malign neoplastik jarayon mavjud edi. Tadqiqotga kiritilgan 162 (80,2%) bemorda qisqa muddatli, bir yilgacha bo'lgan xavfli o'sma tarixi bor edi. 15 (7,4%) bemorda plevra suyuqligining to'planishi kasallikning boshlanishidan bir yil o'tgach o'simta o'sishining rivojlanishiga to'g'ri keldi. 25 (12,4%) bemorda davolanish vaqtida mahalliy nazoratga erishilmadi.
Библиографические ссылки
Ault M.J., Rosen B.T., Scher J., Feinglass J., Barsuk J.H. Thoracentesis outcomes: A 12-year experience. Thorax. 2015;70:127–132.
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424.
Havelock T., Teoh R., Laws D., Gleeson F. Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65:i61–i76.
Kindler H.L., Ismaila N., Armato S.G., Bueno R., Hesdorffer M., Jahan T., Jones C.M., Miettinen M., Pass H., Rimner A., et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018;36:1343–1373.
Roberts ME, Neville E, Berristford RG, et al. Management of malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32–ii40.
Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 National Inpatient Sample. Chest 2017; 151: 845–854
U.S. National Medical Library. "Pleural Disorders." MedlinePlus. Bethesda, Maryland;
Vidmayer, Erik P. Raff, Xershel; Strang, Kevin T. (2006). Vander's Human Physiology: Mechanisms of Body Activity (10th ed.). Boston, Massachusetts: McGraw-Hill. ISBN 978-0072827415.
^ Kasha, Aaron R .; Caruana-Gauci, Roberto; Mansh, Alexander; Gausi, Marilyn; Chetketi, Stanley; Bertolachini, Luke; Skarchi, Marco (April 2017). "The theory of pleural pressure has been revised: the role of capillary balance." Journal of Chest Disease. 9 (4): 979–989. doi: 10.21037 / jtd.2017.03.112. ISSN 2072-1439. PMC 5418293. PMID 28523153.
^ Boron, Walter F .; Boulpaep, Emil L. (2015). Fisiologia medica (2). Elsevier Mosbi. ISBN 978-85-352-6851-5. OCLC 949753083.
^ Lay-Fuk, Stephen J. (April 2004). "Pleural Mechanics and Fluid Exchange." Physiological reviews. 84 (2): 385–410. doi: 10.1152 / physrev.00026.2003. ISSN 0031-9333. PMID 15044678.
